Top Markets
#1 Cortex Cortex +363.16%
#2 bitcastle Token bitcastle Token +152.95%
#3 MarsCoin MarsCoin +83.47%
#4 MowCat MowCat +69.98%
#5 Useless Coin Useless Coin +57.30%
#6 Palladium Network Palladium Network +53.33%
#7 edgeX edgeX +40.48%
#8 Bedrock Bedrock +33.56%
#9 Pons Pons +29.06%
#10 UnityWallet Token UnityWallet Token +28.24%
Coin of the day
Cortex Cortex
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Clasificación en acciones #17257
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Precio por acción
$1.36
Capitalización bursátil
$251.30M
Cambio (1 día)
-1.72%
Cambio (1 año)
-22.50%
País
US
Comercio Neumora Therapeutics, Inc. Common Stock (NMRA)

Categoría

Healthcare
Ganancias de Neumora Therapeutics, Inc. Common Stock (NMRA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Neumora Therapeutics, Inc. Common Stock, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Neumora Therapeutics, Inc. Common Stock desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH